{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:34:52Z","timestamp":1789626892769,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13300-026-01864-6","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T09:22:29Z","timestamp":1775640149000},"page":"753-770","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Effectiveness and Safety of Escalating Once-Weekly Semaglutide from 0.5 to 1.0\u00a0mg in Type 2 Diabetes"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7873-8988","authenticated-orcid":false,"given":"Genki","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-918X","authenticated-orcid":false,"given":"Hiroshi","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Takuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2605-608X","authenticated-orcid":false,"given":"Manabu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8461-2246","authenticated-orcid":false,"given":"Ayako","family":"Fuchigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2836-0189","authenticated-orcid":false,"given":"Yoko","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukumi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6293-5010","authenticated-orcid":false,"given":"Takahisa","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"1864_CR1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2025","unstructured":"International Diabetes Federation. IDF Diabetes Atlas. 11th ed. Brussels: International Diabetes Federation; 2025.","edition":"11"},{"key":"1864_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S2213-8587(20)30431-9","volume":"9","author":"J Pearson-Stuttard","year":"2021","unstructured":"Pearson-Stuttard J, Bennett J, Cheng YJ, Vamos EP, Cross AJ, Ezzati M, et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. Lancet Diabetes Endocrinol. 2021;9:165\u201373. https:\/\/doi.org\/10.1016\/S2213-8587(20)30431-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"1864_CR3","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Suppl 1):S181\u2013206. https:\/\/doi.org\/10.2337\/dc25-S009.","journal-title":"Diabetes Care"},{"key":"1864_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1603827.","journal-title":"N Engl J Med"},{"key":"1864_CR5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1607141.","journal-title":"N Engl J Med"},{"key":"1864_CR6","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(18)32261-X.","journal-title":"Lancet"},{"key":"1864_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"1864_CR8","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269.","journal-title":"N Engl J Med"},{"key":"1864_CR9","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2501006.","journal-title":"N Engl J Med"},{"key":"1864_CR10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251\u201360. https:\/\/doi.org\/10.1016\/S2213-8587(17)30013-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1864_CR11","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341\u201354. https:\/\/doi.org\/10.1016\/S2213-8587(17)30092-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1864_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258\u201366. https:\/\/doi.org\/10.2337\/dc17-0417.","journal-title":"Diabetes Care"},{"key":"1864_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, Pileti\u010d M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355\u201366. https:\/\/doi.org\/10.1016\/S2213-8587(17)30085-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1864_CR14","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291\u2013301. https:\/\/doi.org\/10.1210\/jc.2018-00070.","journal-title":"J Clin Endocrinol Metab"},{"key":"1864_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275\u201386. https:\/\/doi.org\/10.1016\/S2213-8587(18)30024-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1864_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","volume":"63","author":"RJ McCrimmon","year":"2020","unstructured":"McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, et al. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473\u201385. https:\/\/doi.org\/10.1007\/s00125-019-05065-8.","journal-title":"Diabetologia"},{"key":"1864_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356\u201367. https:\/\/doi.org\/10.1016\/S2213-8587(19)30066-X.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1864_CR18","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46:100\u20139. https:\/\/doi.org\/10.1016\/j.diabet.2019.101117.","journal-title":"Diabetes Metab"},{"key":"1864_CR19","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40618-022-01799-2","volume":"45","author":"P Marzullo","year":"2022","unstructured":"Marzullo P, Daffara T, Mele C, Zavattaro M, Ferrero A, Caputo M, et al. Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. J Endocrinol Investig. 2022;45:1587\u201398. https:\/\/doi.org\/10.1007\/s40618-022-01799-2.","journal-title":"J Endocrinol Investig"},{"key":"1864_CR20","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.pcd.2021.06.008","volume":"15","author":"N Rajamand Ekberg","year":"2021","unstructured":"Rajamand Ekberg N, Bodholdt U, Catarig AM, Catrina SB, Grau K, Holmberg CN, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark\/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15:871\u20138. https:\/\/doi.org\/10.1016\/j.pcd.2021.06.008.","journal-title":"Prim Care Diabetes"},{"key":"1864_CR21","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s13300-022-01313-0","volume":"13","author":"H Yamada","year":"2022","unstructured":"Yamada H, Yoshida M, Suzuki D, Funazaki S, Nagashima S, Masahiko K, et al. Effectiveness and safety of once-weekly semaglutide in Japanese patients with type 2 diabetes in treatment intensification: a retrospective observational single-center study. Diabetes Ther. 2022;13:1779\u201388. https:\/\/doi.org\/10.1007\/s13300-022-01313-0.","journal-title":"Diabetes Ther"},{"key":"1864_CR22","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.3390\/nu16152545","volume":"16","author":"I Caballero Mateos","year":"2024","unstructured":"Caballero Mateos I, Garc\u00eda de Lucas MD, Doulatram-Gamgaram VK, Moreno-Moreno P, Jimenez-Millan AI, Botana-L\u00f3pez M, et al. Real-world evaluation of once-weekly subcutaneous semaglutide in patients with type 2 diabetes mellitus in Spain (SEMA-RW study). Nutrients. 2024;16:2545. https:\/\/doi.org\/10.3390\/nu16152545.","journal-title":"Nutrients"},{"key":"1864_CR23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.36469\/001c.124111","volume":"11","author":"NN Gronroos","year":"2024","unstructured":"Gronroos NN, Swift C, Frazer MS, Sargent A, Leszko M, Buysman E, et al. Real-world HbA1c changes among type 2 diabetes mellitus patients initiating treatment with a 1.0 mg weekly dose of semaglutide for diabetes. J Health Econ Outcomes Res. 2024;11:118\u201324. https:\/\/doi.org\/10.36469\/001c.124111.","journal-title":"J Health Econ Outcomes Res"},{"key":"1864_CR24","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.3390\/jcm11174938","volume":"11","author":"V Bellido","year":"2022","unstructured":"Bellido V, Abreu Pad\u00edn C, Catarig AM, Clark A, Barreto Pittol S, Delgado E. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE Spain multicentre, prospective, observational study. J Clin Med. 2022;11:4938. https:\/\/doi.org\/10.3390\/jcm11174938.","journal-title":"J Clin Med"},{"key":"1864_CR25","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1111\/dom.15020","volume":"25","author":"R Napoli","year":"2023","unstructured":"Napoli R, Berra C, Catarig AM, Di Loreto C, Donatiello E, Berentzen TL, et al. Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab. 2023;25:1658\u201367. https:\/\/doi.org\/10.1111\/dom.15020.","journal-title":"Diabetes Obes Metab"},{"key":"1864_CR26","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s13300-024-01631-5","volume":"15","author":"G Sato","year":"2024","unstructured":"Sato G, Uchino H, Hirose T. Efficacy and safety of escalating the dose of oral semaglutide from 7 to 14 mg: a single-center, retrospective observational study. Diabetes Ther. 2024;15:2119\u201330. https:\/\/doi.org\/10.1007\/s13300-024-01631-5.","journal-title":"Diabetes Ther"},{"key":"1864_CR27","doi-asserted-by":"publisher","first-page":"e466","DOI":"10.1016\/j.orcp.2013.10.003","volume":"8","author":"A Muramoto","year":"2014","unstructured":"Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, Nakamura M, et al. Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract. 2014;8:e466\u201375. https:\/\/doi.org\/10.1016\/j.orcp.2013.10.003.","journal-title":"Obes Res Clin Pract"},{"key":"1864_CR28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","volume":"50","author":"P Newsome","year":"2019","unstructured":"Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity. Aliment Pharmacol Ther. 2019;50:193\u2013203. https:\/\/doi.org\/10.1111\/apt.15316.","journal-title":"Aliment Pharmacol Ther"},{"key":"1864_CR29","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kj\u00e6r MS, Krarup N, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511\u201322. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1864_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pcd.2024.03.005","volume":"18","author":"L Fang","year":"2024","unstructured":"Fang L, Li J, Zeng H, Liu J. Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: a systematic review and meta-analysis. Prim Care Diabetes. 2024;18:268\u201376. https:\/\/doi.org\/10.1016\/j.pcd.2024.03.005.","journal-title":"Prim Care Diabetes"},{"key":"1864_CR31","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2337\/diabetes.51.6.1889","volume":"51","author":"B Vozarova","year":"2002","unstructured":"Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51:1889\u201395. https:\/\/doi.org\/10.2337\/diabetes.51.6.1889.","journal-title":"Diabetes"},{"key":"1864_CR32","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2337\/db10-1806","volume":"60","author":"F Bonnet","year":"2011","unstructured":"Bonnet F, Ducluzeau PH, Gastaldelli A, Laville M, Anderwald CH, Konrad T, et al. Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. Diabetes. 2011;60:1660\u20137. https:\/\/doi.org\/10.2337\/db10-1806.","journal-title":"Diabetes"},{"key":"1864_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2362.2005.01502.x","volume":"35","author":"RK Schindhelm","year":"2005","unstructured":"Schindhelm RK, Diamant M, Bakker SJ, van Dijk RA, Scheffer PG, Teerlink T, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Investig. 2005;35:369\u201374. https:\/\/doi.org\/10.1111\/j.1365-2362.2005.01502.x.","journal-title":"Eur J Clin Investig"},{"key":"1864_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6823-12-16","volume":"12","author":"MA G\u00f3mez-S\u00e1mano","year":"2012","unstructured":"G\u00f3mez-S\u00e1mano MA, Cuevas-Ramos D, Mehta R, Brau-Figueroa H, Meza-Arana CE, Gulias-Herrero A. Association of alanine aminotransferase levels (ALT) with the Hepatic Insulin Resistance Index (HIRI): a cross-sectional study. BMC Endocr Disord. 2012;12:16. https:\/\/doi.org\/10.1186\/1472-6823-12-16.","journal-title":"BMC Endocr Disord"},{"key":"1864_CR35","doi-asserted-by":"publisher","first-page":"g4596","DOI":"10.1136\/bmj.g4596","volume":"349","author":"N Sattar","year":"2014","unstructured":"Sattar N, Forrest E, Preiss D. Non-alcoholic fatty liver disease. BMJ. 2014;349:g4596. https:\/\/doi.org\/10.1136\/bmj.g4596.","journal-title":"BMJ"},{"key":"1864_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391:109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2403347.","journal-title":"N Engl J Med"},{"key":"1864_CR37","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1371\/journal.pmed.0040296","volume":"4","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296. https:\/\/doi.org\/10.1371\/journal.pmed.0040296.","journal-title":"PLoS Med"},{"key":"1864_CR38","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","volume":"12","author":"EI Benchimol","year":"2015","unstructured":"Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12:e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885.","journal-title":"PLoS Med"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01864-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:31:05Z","timestamp":1778229065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01864-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1864"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01864-6","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"15 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Genki Sato has nothing to disclose. Hiroshi Uchino has nothing to disclose. Kota Takuma has nothing to disclose. Manabu Saito has nothing to disclose. Ayako Fuchigami has nothing to disclose. Yoko Iwata has nothing to disclose. Fukumi Yoshikawa has received speaker honoraria from Novo Nordisk Pharma Ltd. and Sumitomo Pharma Co., Ltd. Takahisa Hirose has received research grants from Sumitomo Pharma Co., Ltd. and Boehringer Ingelheim Japan and speaker honoraria from Novo Nordisk Pharma Ltd., MSD K.K., Sumitomo Pharma Co., Ltd., Kowa Co., Ltd., Sanofi K.K., Eli Lilly Japan K.K., Mitsubishi Tanabe Pharma Corporation, and Abbott Japan LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures in this study were performed in accordance with the tenets of the Declaration of Helsinki as revised in 2024. The study was approved by the Ethics Committee of the Faculty of Medicine, Toho University (No. T2024-2415). This study used retrospective non-identifiable data obtained by the treating physicians; therefore, based on the decision of the local Ethics Committee of Toho University Omori Medical Center, informed consent was not required. Patients were allowed to object to the use of their data for retrospective scientific research; however, none objected.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}